Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study.

Cancers (Basel) · 2022 · PMC9735435 · PMID 36497493

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Likewise, even if only showing a strong trend for formal statistical significance, the ECOG-PS 2 patients undergoing IO-based treatments exhibited a poorer survival (12.1 (95% CI, 3.9–20.4) months vs.

also in 5,725 other papers

a significant trendno p-value reported

Similarly, the patients with a poorer PS receiving IO-based treatments had a numerically shorter median PFS while showing a significant trend for statistical significance (6.1 (95% CI, 0.6–11.5) months vs.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.